FDA Approves New Treatment for CLL

The FDA has granted accelerated
approval for GlaxoSmithKline and
Genmab’s Arzerra™ (ofatumumab)
for people with chronic lymphocytic
leukemia whose cancer is no longer
being controlled by other forms of
chemotherapy. Arzerra is a monoclonal
antibody that causes the body’s
immune response to fight against both
normal and malignant B cells.

The manufacturer is currently conducting
a clinical trial in people with
CLL to confirm that the addition of
Arzerra to standard chemotherapy delays
the progression of the disease.

♦ ♦ ♦ ♦ ♦

This article was published in Coping® with Cancer magazine,
January/February
2010.